Selected-GenAtlas references	SOURCE	GeneCards	NCBI Gene	Swiss-Prot	Ensembl
	HGNC	UniGene	Nucleotide	OMIM	UCSC

Home Page

FLASH GENE

Symbol

ADAM12

contributors: mct/ - updated : 04-01-2017

HGNC name	ADAM metallopeptidase domain 12
HGNC id	190

FLASH GENE DNA RNA EXPRESSION PROTEIN DISORDER ANIMAL & CELL MODELS

ASSOCIATED DISORDERS

corresponding disease(s)

Other morbid association(s)

Type Gene Modification Chromosome rearrangement Protein expression Protein Function tumoral     --other   aberrantly expressed in breast cancer patient urine, and increased urinary levels correlate with breast cancer progression tumoral     --over   in gastric carcinoma constitutional     --over   in osteoarthritic cartilage and enhances IGF1-mediated chondrocyte proliferation by degradation of insulin-like growth factor-binding protein IGFBP5 constitutional     --over   fivefold upregulated in the nonhealing edge of chronic ulcers compared to healthy skin tumoral     --low   hypomethylated in Triple-negative breast cancer (TNBC)

Susceptibility

to late-onset Alzheimer disease

Variant & Polymorphism other	interaction between the ADAM12 and SH3PXD2A genes may confer susceptibility to late-onset Alzheimer disease

Candidate gene	for rapid diagnostic of cancer (detection of urinary ADAM 12 may prove useful in the development of noninvasive diagnostic and prognostic tests for breast and perhaps other cancers)
	can be detected in the urine of breast and bladder cancer patients, and its levels have been shown to correlate with disease status, stage, and cancer risk
Marker	urinary MMP9/LCN2 and ADAM12 are potential noninvasive biomarkers for gastric cancer, including early-stage disease
	serum BSG and ADAM12 values and urine ADAM12 values may be useful markers in prostate cancer
	is a promising marker for the diagnosis of complete spontaneous abortion and ectopic pregnancy in symptomatic women, and under certain conditions, ADAM12 can diagnose ectopic pregnancy and spontaneous abortion before an ultrasonographic detection of the conditions
	ADAM12L may serve as a novel marker and/or a novel therapeutic target in breast tumor-initiating cells (BTICs)
	ADAM12 hypomethylation could be a poor outcome biomarker in Triple-negative breast cancer (TNBC)
Therapy target
	System Type Disorder Pubmed cancer reproductive breast may represent a potential therapeutic target in breast cancer immunology autoimmune articular treatment of patients with the heparin analog CaPPS may promote ADAM12 degradation of IGFBP 3 and stimulate chondrocyte proliferation in osteoarthritic cartilage cancer digestive oesophagus ADAM12L might be potential targets of esophageal carcinoma for anti-metastasis therapy miscelleaneous dermatology   topical ADAM12 inhibitors may therefore prove useful for the treatment of chronic wounds cancer reproductive breast potential therapeutic target in Triple-negative breast cancer (TNBC

ANIMAL & CELL MODELS